pp-022 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
China
Comments
Indication: Autoimmune diseases (e.g., adult systemic lupus erythematosus, primary Sjögren’s syndrome, inflammatory bowel diseases), Phase 1 (subcutaneous injection in healthy adults and disease populations), humanised anti-PD-1 monoclonal antibody (PD-1 agonist). Administration: Subcutaneous injection multiple‐ascending dose trials
Manufacturer #7041
This pioneering genetic-engineering–based pharmaceutical company is known for its advances in child and women’s health, supported by nearly three decades of experience in biopharmaceuticals and innovative drug development. It operates tech-driven R&D platforms with over 80 pipeline projects and more than 120 marketed products. The organization is expanding into additional high-need therapeutic areas, including endocrinology, immunology and oncology, while actively pursuing global innovation and commercial partnerships.
Manufacturer usually replies in 74 days